-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Live Q&A

Program: Scientific Workshops @ ASH
Session: Engineered Immune Cells in the Management of Lymphoid Malignancies
Wednesday, December 2, 2020, 8:20 AM-9:55 AM

Larry W. Kwak, MD, PhD

Deputy Director, City of Hope Comprehensive Cancer Center, Duarte, CA

Disclosures: Kwak: Sellas Life Sciences Grp: Consultancy; Enzychem Life Sciences: Membership on an entity's Board of Directors or advisory committees; Antigenics: Other: equity; InnoLifes, Inc: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Pepromene Bio: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Theratest: Current equity holder in private company; Celltrion, Inc.: Consultancy; CJ Healthcare: Consultancy; Celltrion Healthcare: Membership on an entity's Board of Directors or advisory committees.

See more of: Engineered Immune Cells in the Management of Lymphoid Malignancies
See more of: Scientific Workshops @ ASH
<< Previous Presentation | Next Presentation >>